[MS7-3C-2] Quantitative Muscle Ultrasound vs. Magnetic Resonance Imaging in Duchenne Muscular Dystrophy
[Introduction] It is a need for biomarkers to help characterize the disease process and monitor the effects of treatment, as new therapeutic approaches become available for the boys with Duchenne muscular dystrophy (DMD). This study aimed to evaluate whether Quantitative muscle ultrasound (QMUS) or magnetic resonance imaging (MRI), or composite of them provides more effective follow-up tool for DMD progression and therapeutic response in clinical trials.
[Methodology] In the longitudinal observational cohort study, the changes of the right quadriceps femoris (QF) muscle thickness (MT) and echo intensity (EI) in QMUS and T1-weighted MRI grading were measured according to the changes of clinical characteristics, including muscle strength, timed functional testing, and the quality of life (QoL) questionnaire in the boys with DMD used prednisone from baseline to 12th month.
[Results] The right QF muscle changes of MT and EI in QMUS and T1-weighted MRI had significant relations with the changes of the clinical characteristics, including muscle strength, timed functional testing, and QoL in 36 boys with DMD (4-7 years) used prednisone from baseline to 12th month (P<0.05). In addition, There were good correlations of the right QF muscle changes between MT and EI in QMUS and T1-weighted MRI grading (P<0.05).
[Conclusions] Both QMUS and MRI can be used to measure DMD progression and therapeutic response in clinical trials. QMUS is more suited for longitudinal follow-up treatment trials and MRI is a good tool for diagnostic purposes in DMD.
[Methodology] In the longitudinal observational cohort study, the changes of the right quadriceps femoris (QF) muscle thickness (MT) and echo intensity (EI) in QMUS and T1-weighted MRI grading were measured according to the changes of clinical characteristics, including muscle strength, timed functional testing, and the quality of life (QoL) questionnaire in the boys with DMD used prednisone from baseline to 12th month.
[Results] The right QF muscle changes of MT and EI in QMUS and T1-weighted MRI had significant relations with the changes of the clinical characteristics, including muscle strength, timed functional testing, and QoL in 36 boys with DMD (4-7 years) used prednisone from baseline to 12th month (P<0.05). In addition, There were good correlations of the right QF muscle changes between MT and EI in QMUS and T1-weighted MRI grading (P<0.05).
[Conclusions] Both QMUS and MRI can be used to measure DMD progression and therapeutic response in clinical trials. QMUS is more suited for longitudinal follow-up treatment trials and MRI is a good tool for diagnostic purposes in DMD.